Jan 28, 2025 · Orphan drug designation offers development incentives and potential market exclusivity

Jan 28, 2025 · The great table of debate has been pulled up, as argument and counter argument wrestle for supremacy in the first tubthumping PharmaTimes of the year. Indeed, we stare down all the most pressing issues of 2025 including AI, modern comms, misinformation, mass screening, weight loss drugs, the future of the NHS, digital drugs and the promised land of patient inclusivity. Yep, this year – more ...

How industry and the NHS can work together to bridge the diagnostic gap in COPD

Jan 28, 2025 · The great table of debate has been pulled up, as argument and counter argument wrestle for supremacy in the first tubthumping PharmaTimes of the year. Indeed, we stare down all the most pressing issues of 2025 including AI, modern comms, misinformation, mass screening, weight loss drugs, the future of the NHS, digital drugs and the promised land of patient inclusivity. Yep, this year – more ...

Jan 27, 2025 · Discover the latest articles published by PharmaTimes Magazine. Browse and customize the article feed to your preferences and explore latest trends

December 2024 - PharmaTimes The Christmas edition arrives but once a year and, as the cover boldly suggests, this is the Christmas edition! Within the pages of our frost encrusted periodical, we will find 12 industry luminaries issuing wistful recollections of the year just passed, while embarking on a dalliance with the future. And, mark my words, if the prophecies of these prophetic prophets ...

3 days ago · Patients and care partners may find once every four weeks maintenance dosing easier

MHRA urges caution over illegal medicines from beauty salons and social media

Jan 28, 2025 · The US Food and Drug Administration (FDA) has approved Eisai and Biogen’s Supplemental Biologics License Application for once every four weeks intravenous (IV) maintenance dosing of LEQEMBI (lecanemab-irmb) for early Alzheimer’s disease (AD). This decision may simplify the treatment process for patients and care partners. LEQEMBI, designed for patients with mild cognitive impairment (MCI ...

PharmaTimes Magazine PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative and trustworthy content through impartial, balanced and informed opinion and analysis. PharmaTimes print and digital magazine has a distributed circulation of 19,000 ...